About us

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

United States

C5-6 Technologies LLC.

Send an Email

Phillip Brumm

Address:

C5-6 Technologies LLC 
5627 Old Oak Drive Fitchburg, 
WI 53711 USA.

Research Interests:

  • Enzymes
  • Comparative Genomics
  • Functional Genomics
  • Carbohydrate Chemistry
  • Glycobiology
  • Genome Annotation
  • Gene Annotation
  • Enzyme Engineering
  • Functional Annotation

Biography:

  • Throughout my career, I have had an interest in the relationship between structure and function in living systems, particularly in the areas of proteins. 
  • My graduate work studied the enzymology of vitamin B12 biosynthesis. In industry, I continued to pursue this interest by studying the relationships of starch-degrading enzymes with their substrates. 
  • Eventually, I became head of research for an industrial enzyme company with $50M in sales, Enzyme Bio-Systems, Ltd., which is now a part of Dow-Danisco. 
  • The work I performed there led to three new enzyme products with over $10M in sales as well as developing a maltodextrin business for the parent company. 
  • After Enzyme Bio-Systems was sold, I moved to Lucigen Corp. to work on purification and characterization of enzymes involved in nucleic acid synthesis.
  •  Part of the work at Lucigen focused on discovery of new organisms as potential sources for these nucleic acid enzymes. 
  • The new organisms discovered in my work led to the formation of C5o6 Technologies, Inc., a spin-out from Lucigen.
  •  As the Chief Scientific Officer for C5o6 Technologies, Inc., I had overall responsibility for research focused on the identification, cloning, and characterization of novel microbial carbohydrases through both random shotgun screening of organisms and whole genome mining of organisms. 
  • These enzymes have been patented and commercialized for applications in research, biofuels production, and biomedical applications. 
  • We partnered with commercial and academic laboratories to advance our understanding of the structure and function of these newly discovered enzymes and to develop additional commercial applications for them. 
  • C5o6 Technologies, Inc. was dissolved in 2014, and I purchased the assets in 2015 to continue the work of identifying carbohydrases with potential antimicrobial and antibiofilm activities that I started. 
  • At the new company C5-6 Technologies, LLC, I collaborating with UW Pharmacy staff and an antibiotic company to move the first antimicrobial enzymes into clinical trials. 
  • I am also assisting a start-up in Madison identify and develop new enzymes for capture and sequencing of large DNA molecules. www.c56technologies.com also: LinkedIn.com Researchgate.com and academia.edu.